|
Sign In to gain access to subscriptions and/or personal tools.
|
Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis
DG Wahl
Service de Medicine H., Nancy University Hospital, Nancy, France
F. Guillemin
School of Public Health, Faculty of Medicine, Vandoeuvre-les-Nancy, France
E. de Maistre
Laboratory of Haemostasis and Thrombosis, Nancy University Hospital, Nancy, France
C. Perret
Service de Medicine H., Nancy University Hospital, Nancy, France
T. Lecompte
Laboratory of Haemostasis and Thrombosis, Nancy University Hospital, Nancy, France
G. Thibaut
Service de Medicine H., Nancy University Hospital, Nancy, France
Objective: To describe the relative risk for venous thrombosis (VT) associated with antiphos pholipid antibodies (aPL) in systemic lupus erythematosus (SLE).
Design: Systematic review and meta-analysis of 26 articles that examined the association between aPL and VT in SLE.
Setting: Mostly secondary and tertiary referral centres.
Patients: 2249 patients with SLE, 1120 tested for LA (lupus anticoagulant) and 1563 tested for aCL (anticardiolipin antibodies).
Main outcome measures: A summary of study characteristics and a critical appraisal of study quality were done. Two statistical combinations of 18 primary studies that examined the association of VT and LA and of 14 studies that examined the association of VT and aCL were performed to estimate the risk for VT associated with aPL.
Results: The odds ratios of the risk of VT related to the LA summarized from 18 studies were 5.61 [95% CI; 3.80-8.27] overall, 6.32 [CI; 3.71-10.78] for deep venous thrombosis and pulmonary embolism, 11.6 [3.65--36.91] for recurrent venous thrombosis after the first event. The odds ratios of the risk of VT related to aCL summarized from 14 studies were 2.17 [95% CI; 1.51-3.11] overall, 2.50 [CI; 1.51-4.14] for deep venous thrombosis and pulmonary embolism, 3.91 [1.14- 13.38] for recurrent venous thrombosis after the first event.
Conclusions: Patients with SLE and LA are at approximately six times greater risk for VT than patients without LA, whereas patients with SLE and aCL are approximately two times greater risk for VT than patients without aCL. We have identified important methodologic limitations and differences in study characteristics. Other risk factors for VT have not been thoroughly evaluated in these studies. Further studies are needed that provide an accurate estimate of the absolute risk for aPL related VT.
Key Words: systemic lupus erythematosus • Hughes syndrome • anticardiolipin antibodies • lupus anticoagulant • venous thrombosis
Lupus, Vol. 6, No. 5,
467-473 (1997)
DOI: 10.1177/096120339700600510
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Giannakopoulos and S. A. Krilis
How I treat the antiphospholipid syndrome
Blood,
September 3, 2009;
114(10):
2020 - 2030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hasegawa, M. Caleiro, R Fuller, and J. Carvalho
The frequency of anti-{beta}2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease
Lupus,
June 1, 2009;
18(7):
618 - 621.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. DANOWSKI, M. N. L. de AZEVEDO, J. A. de SOUZA PAPI, and M. PETRI
Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus
J Rheumatol,
June 1, 2009;
36(6):
1195 - 1199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Farmer-Boatwright and R. A.S. Roubey
Venous Thrombosis in the Antiphospholipid Syndrome
Arterioscler Thromb Vasc Biol,
March 1, 2009;
29(3):
321 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Giannakopoulos, F. Passam, Y. Ioannou, and S. A. Krilis
How we diagnose the antiphospholipid syndrome
Blood,
January 29, 2009;
113(5):
985 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Matsuura and L. Lopez
Autoimmune-mediated atherothrombosis
Lupus,
October 1, 2008;
17(10):
879 - 888.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Membre, D. Wahl, V. Latger-Cannard, J.-P. Max, P. Lacolley, T. Lecompte, and V. Regnault
The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies
Haematologica,
April 1, 2008;
93(4):
566 - 573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Swigris, A. Fischer, J. Gilles, R. T. Meehan, and K. K. Brown
Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus
Chest,
January 1, 2008;
133(1):
271 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Wahl and V. Regnault
Treatment of antiphospholipid antibody syndrome.
JAMA,
July 5, 2006;
296(1):
42 - 43.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M L Bertolaccini and M A Khamashta
Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Lupus,
March 1, 2006;
15(3):
172 - 178.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Male, D. Foulon, H. Hoogendoorn, P. Vegh, E. Silverman, M. David, and L. Mitchell
Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus
Blood,
December 15, 2005;
106(13):
4152 - 4158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Petri
Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort
Lupus,
December 1, 2005;
14(12):
970 - 973.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. T. Ho, C. W. Ahn, G. S. Alarcon, B. A. Baethge, F. K. Tan, J. Roseman, H. M. Bastian, B. J. Fessler, G. McGwin Jr, L. M. Vila, et al.
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events
Rheumatology,
October 1, 2005;
44(10):
1303 - 1307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Matsuura, K Kobayashi, K Inoue, L R Lopez, and Y Shoenfeld
Oxidized LDL/{beta}2-glycoprotein I complexes: new aspects in atherosclerosis
Lupus,
September 1, 2005;
14(9):
736 - 741.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. L. Ortel
Thrombosis and the Antiphospholipid Syndrome
Hematology,
January 1, 2005;
2005(1):
462 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Parke
Short and long-term maternal outcomes in patients with phospholipid antibodies
Lupus,
September 1, 2004;
13(9):
703 - 704.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. N Bruce
Coronary heart disease (CHD) in lupus: round up the usual suspects?
Lupus,
August 1, 2004;
13(8):
557 - 560.
[PDF]
|
|
|
|
|
|
|
M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2004;
10(2):
89 - 126.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Tripodi, A. Biasiolo, V. Chantarangkul, and V. Pengo
Lupus Anticoagulant (LA) Testing: Performance of Clinical Laboratories Assessed by a National Survey Using Lyophilized Affinity-purified Immunoglobulin with LA Activity
Clin. Chem.,
October 1, 2003;
49(10):
1608 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Barcat, V Guerin, A Ryman, J Constans, J P Vernhes, C Vergnes, F Bonnet, X Delbrel, P Morlat, M Longy-Boursier, et al.
Thrombophilia and thrombosis in systemic lupus erythematosus: a case-control study
Ann Rheum Dis,
October 1, 2003;
62(10):
1016 - 1017.
[Full Text]
|
|
|
|
|
|
|
J. G. Hanly
Antiphospholipid syndrome: an overview
Can. Med. Assoc. J.,
June 24, 2003;
168(13):
1675 - 1682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Galli, D. Luciani, G. Bertolini, and T. Barbui
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
Blood,
March 1, 2003;
101(5):
1827 - 1832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jankowski, I. Vreys, C. Wittevrongel, D. Boon, J. Vermylen, Marc. F. Hoylaerts, and J. Arnout
Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster
Blood,
January 1, 2003;
101(1):
157 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G. I. Jennekens and L. Kater
The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation
Rheumatology,
June 1, 2002;
41(6):
619 - 630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Levine, D. W. Branch, and J. Rauch
The Antiphospholipid Syndrome
N. Engl. J. Med.,
March 7, 2002;
346(10):
752 - 763.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Male, L. Mitchell, J. Julian, P. Vegh, P. Joshua, M. Adams, M. David, and M. E. Andrew
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus
Blood,
February 15, 2001;
97(4):
844 - 849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Shrivastava, S Dwivedi, A Aggarwal, and R Misra
Anti-cardiolipin and anti-beta 2 glycoprotein Iantibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures
Lupus,
January 1, 2001;
10(1):
45 - 50.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. G. Wahl, H. Bounameaux, P. de Moerloose, and F. P. Sarasin
Prophylactic Antithrombotic Therapy for Patients With Systemic Lupus Erythematosus With or Without Antiphospholipid Antibodies: Do the Benefits Outweigh the Risks? A Decision Analysis
Arch Intern Med,
July 10, 2000;
160(13):
2042 - 2048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D G Wahl, F Guillemin, E de Maistre, C Perret-Guillaume, T Lecompte, and G Thibaut
Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis
Lupus,
January 1, 1998;
7(1):
15 - 22.
[Abstract]
[PDF]
|
|
|
|
|
